• Ann. Intern. Med. · Aug 2024

    Comment Randomized Controlled Trial

    In ASCVD, an inclisiran-first strategy reduced LDL-C levels and statin discontinuation at 330 d.

    • Ellis Lader.
    • WMC Health Heart and Vascular Institute, Kingston Division of Cardiology, Kingston, New York, USA (E.L.).
    • Ann. Intern. Med. 2024 Aug 1; 177 (8): JC89JC89.

    AbstractKoren MJ, Rodriguez F, East C, et al. An "inclisiran first" strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83:1939-1952. 38593947.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!

We guarantee your privacy. Your email address will not be shared.